Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2015

View Archived Issues

Mitochondrial uncoupling has disease-modifying effects in mouse models of type 2 diabetes

Ultra-small nanoparticle probe for cancer diagnostics

Janssen Biotech forms license agreement with Vedanta Biosciences for VE-202

Moderna and Merck & Co. to develop mRNA-based antiviral treatments and vaccines

KalGene enters license agreement with NRC to develop Alzheimer's therapeutics

DSMB recommends continuation of phase III trial of masitinib for ALS

Catabasis patents novel fatty acid-drug conjugates for cancer

AstraZeneca's PEGASUS-TIMI 54 trial of Brilinta meets primary endpoint

Alnylam's RNAi therapy targeting antithrombin improves clotting in patients with hemophilia

Auris Medical updates on phase III trial of AM-101 in tinnitus

NantCell licenses anti-IGF-I receptor antibody ganitumab from Amgen

Companies investigate different approaches to tackling Ebola

Treeway and uniQure collaborate to develop gene therapy for ALS

FDA grants orphan drug status to OS-2966 and ulocuplumab for cancer

Intestinal FXR triggering mimics food intake and improves metabolic disease

Takeda divulges PK-R1 antagonists

Roche reports development of agents for psychiatric disorders

Orion prepares new androgen receptor and CYP17 inhibitors for prostate cancer

Cadila Pharmaceuticals presents novel MPGES-1 inhibitors

OncoMed enrolls first biomarker-selected patient in anti-Notch 1 expansion trial

Alexion describes pipeline outlook at JP Morgan Healthcare Conference

European Alzheimer's disease initiative EPAD is launched

Phase I results presented for AMG-377 treatment of gastrointestinal tumors

Neuropore and UCB collaborate in Parkinson's disease

AbbVie's Viekirax plus Exviera receives E.U. approval for chronic HCV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...